Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
CGT9486 + Sunitinib for GIST
Recruiting2 awardsPhase 3
Cleveland, Ohio
This trial will evaluate the efficacy of CGT9486 in combination with sunitinib compared to sunitinib alone in patients with gastrointestinal stromal tumors (GIST) who are intolerant to, or who have failed, prior treatment with imatinib. Approximately 426 patients will be enrolled in this open-label, international, multicenter study.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service